Skip to main content

Table 3 Comparison of 2-year radiographic progression among tumor necrosis factor antagonists

From: Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years

   Baseline characteristics Radiographic progression results
Cohort Numbera Disease duration, yearsb mSASSS valueb Mean mSASSS change from baseline to year 2b Between-cohort Pvalue
Etanercept [2] 257 10 ± 8.5 16 ± 18.3 0.9 ± 2.5 0.996
OASIS 175 11 ± 8.5 14 ± 17.6 1.0 ± 3.2  
Infliximab [3] 156 10.2 ± 8.7 17.7 ± 17.9 0.9 ± 2.6 0.541
OASIS 165 11.3 ± 8.6 15.8 ± 18.1 1.0 ± 3.2  
Adalimumab 307 11.2 ± 9.3 19.8 ± 19.3 0.8 ± 2.6 0.771
OASIS 169 11.3 ± 8.6 15.8 ± 17.6 0.9 ± 3.3  
  1. aNumber of patients with a baseline and a year-2 radiograph. bValues are mean ± standard deviation. mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; OASIS, Outcome in Ankylosing Spondylitis International Study.